European rollout Triojection is CE Marked since 2014 and nearing commercial availability in Europe, indicating a near-term entry point for EU distributors, clinics, and partners seeking non-surgical disc treatment options.

Clinical expansion Company is supporting a multi-center randomized European study comparing Triojection to discectomy, signaling commitment to evidence generation that could drive payer and clinician adoption.

Market entry barriers U.S. market access is not yet available, suggesting opportunities for regional pilots, regulatory planning services, and early-adopter EU strategies before U.S. commercialization.

Target segments Product addresses herniated disc treatment with a non-surgical approach, appealing to spine clinics, pain management specialists, and facilities seeking alternatives to injections or surgery.

Financing landscape Current revenue under $1M with $2M in funding implies room for partners with hardware or service-based sales models, and potential investor interest in scalable medtech distribution.